LataMed AI Corp. (OTC: LMED) provided shareholders with an update on the implementation of its previously announced 5-for-1 forward stock split and mandatory share exchange process. As of July 7, 2026, the Company has submitted all requested information to FINRA, and management anticipates the corporate action may become effective within approximately the next week, subject to FINRA's review and final processing.
The forward stock split will be accompanied by a new CUSIP number, 21116R404, replacing the current CUSIP upon effectiveness. This mandatory exchange will affect shareholders differently based on how they hold their shares.
Shareholders holding shares through brokerage accounts in “street name” generally do not need to take any action, as brokerage firms are expected to process the exchange automatically. Similarly, registered book-entry shareholders with the Company's transfer agent should see their accounts updated automatically to reflect the post-split share balance and new CUSIP.
For physical stock certificate holders, existing certificates will represent the pre-exchange security after the split. When a shareholder submits a certificate for transfer, sale, or exchange, it will be processed under the new CUSIP, and the transfer agent will issue the appropriate number of post-split shares. The Company advises these shareholders to await further instructions from the transfer agent regarding certificate submission procedures and documentation requirements.
Dr. Kevin Rodan Levy, CEO of LataMed AI, stated: “We want to ensure that our shareholders clearly understand how the forward stock split and mandatory exchange process will be implemented. While the vast majority of shareholders are expected to have their shares updated automatically, we believe it is important to provide clear guidance regarding the process for shareholders holding physical stock certificates.”
Dr. Levy added that after the split, management intends to focus on advancing the Company's telemedicine platform and pursuing licensing and commercialization opportunities for its CardioAI, PulmoAI, and NeuroAI artificial intelligence platforms. These initiatives are part of the long-term strategy to build an integrated digital healthcare ecosystem throughout Latin America.
The forward stock split supports the Company's corporate development and strategic initiatives while facilitating the implementation of the new CUSIP and updated capital structure. The Company encourages shareholders with questions to contact their brokerage firm or the Company's transfer agent once detailed instructions become available.
For more information, visit https://latamed.ai or review the Company's SEC filings at www.sec.gov.
